News & Markets | Nirvana Systems Inc.- Part 3

Category Archives for "News & Markets"

What to expect after the Oxford-AstraZeneca COVID-19 vaccine news

U.K.-based drugmaker AstraZeneca AZN, -3.81% said on Monday that the coronavirus vaccine it is developing with the University of Oxford had shown an average efficacy of 70% in the Phase 3 trials, and that it would “immediately prepare regulatory submission” of the data for approval by regulatory authorities around the world, for conditional or early approval.

Continue reading

Retail trade group sees holiday sales up 3.6% to 5.2%, posting ‘strong finish’ to 2020 in spite of pandemic

Consumers begin their Black Friday specials shopping as Macys opens their doors at 5pm on Thanksgiving Day on November 28, 2019 in New York. Bryan R. Smith | AFP | Getty Images Retailers could end up having a strong finish to 2020, despite all of the challenges that the coronavirus pandemic has dealt the industry,… Read More »Retail trade group sees holiday sales up 3.6% to 5.2%, posting ‘strong finish’ to 2020 in spite of pandemic The post Retail trade group sees holiday sales up 3.6% to 5.2%, posting ‘strong finish’ to 2020 in spite of pandemic appeared on Stocks News Feed.

Continue reading

AstraZeneca-Oxford COVID-19 vaccine can be up to 90% effective, late-stage trials show

The vaccine being developed by AstraZeneca and the University of Oxford can prevent 70.4% of people from getting COVID-19, and up to 90% if a lower dose is used. justin tallis/Agence France-Presse/Getty Images AstraZeneca and the University of Oxford said on Monday that their COVID-19 vaccine candidate was found to be as much as 90% effective in preventing infections, according to data from a late-stage clinical trial in the U.K. and Brazil. Interim analysis from the Phase 3 vaccine trial found that the experimental shot is 90% effective when administered as a half dose and then a full dose one month later. Effectiveness falls to 62% when two full doses are administered one month apart. The combined analysis from both dosing regimens showed an average efficacy of 70.4%, said the University of Oxford and drugmaker AstraZeneca AZN, -1.44% AZN, -3.81%. “These findings show that we have an effective vaccine that will save many lives,” said Andrew Pollard, chief investigator of the Oxford Vaccine Trial, in a statement. “Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply,” Pollard added. Prof. Sarah Gilbert, professor of vaccinology at the University of Oxford, said: “The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by SARS-CoV-2.” Read: AstraZeneca’s COVID-19 vaccine shows ‘encouraging’ immune response in older adults AstraZeneca said there were no serious safety events related to the vaccine and it was well tolerated across both dosing regimens. Late-stage clinical trials of the vaccine are continuing in the U.S. Shares in AstraZeneca were down 1.7% in early London trading on Monday. AstraZeneca’s news comes days after drugmaker Pfizer PFE, -0.84% and its German partner BioNTech BNTX, +1.43% requested emergency-use authorization of their COVID-19 vaccine candidate, shown to be 95% effective, in the U.S. on Friday. Read: Pfizer and partner BioNTech to seek emergency-use authorization for COVID-19 vaccine Friday Moderna MRNA, +2.59% has said that its vaccine candidate is 94.5% effective and that the biotech company is also expected to apply for emergency authorization shortly. AstraZeneca’s vaccine candidate can be stored at normal refrigeration temperatures, not needing the supercool storage the Pfizer vaccine requires. “It is hugely significant from a logistics point of view that storage can be achieved at a normal refrigeration temperature of around -3 degrees. This makes it much more scalable and as such easier to deliver on a global scale,” said Michael Hewson, chief market analyst at CMC Markets U.K. Analysts at UBS said AstraZeneca will now try and take its pooled data to regulators that have the ability to grant conditional or early approval. “Given FDA [Food and Drug Administration] guidelines, the U.S. is unlikely to be one of them and the vaccine doesn’t seem to be as effective as the mRNA ones. Storage requirements and manufacturing capacity are a plus though,” the UBS analysts wrote in a note to clients on Monday. U.K. health secretary Matt Hancock said it was “fantastic news” that data on Monday showed that a COVID-19 vaccine developed by AstraZeneca with the University of Oxford could be up to 90% effective. “We’ve got 100 million doses on order and should all that go well, the bulk of the rollout will be in the new year.” Study results More than 20,000 volunteers were involved, half in the U.K., the rest in Brazil. The interim analysis was based on 131 infections among volunteers who received the vaccine and those in a control group who were given a meningitis shot. AstraZeneca and the University of Oxford said they have found no serious COVID-19 cases among any of the 20,000 people who received the shot in the clinical trials in the U.K. and Brazil.   AstraZeneca said it is making “rapid progress” in manufacturing, with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. In parallel, Oxford is submitting the full analysis of the Phase 3 interim data for independent scientific peer review and publication.

Continue reading

Decision on approving Pfizer-BioNTech vaccine to be made in ‘shortest time possible,’ U.K. regulator says

The U.K. has ordered 40 million vaccine doses from Pfizer and BioNTech – enough for up to a third of the population. justin tallis/Agence France-Presse/Getty Images The U.K.’s medicines regulator said on Monday that a decision on whether to approve the Pfizer-BioNTech coronavirus vaccine will be made in the “shortest time possible,” after receiving data on the drug.

Continue reading

Dow closes more than 200 points lower to end down week amid concern over rising Covid cases

Stocks fell on Friday as rising new coronavirus cases, coupled with questions around central-bank funding for key emergency programs, cast doubt on a swift economic recovery. The Dow Jones Industrial Average dropped 219 points, or 0.8%. The S&P 500 dipped 0.7%. The Nasdaq Composite was down 0.4%, erasing an earlier gain. Boeing and Salesforce were… Read More »Dow closes more than 200 points lower to end down week amid concern over rising Covid cases The post Dow closes more than 200 points lower to end down week amid concern over rising Covid cases appeared on Stocks News Feed.

Continue reading

12 million Americans will lose their unemployment benefits the day after Christmas

Retailers have been particularly hard-hit by the coronavirus-induced recession forcing many stores to close, resulting in layoffs. VALERIE MACON/AFP via Getty Images Unemployed Americans have seen their benefits shrink over the past few months, and the holiday season will bring yet another financial blow — and it’s not related to shopping for presents.

Continue reading

The Fed: Fed’s Evans says he’s disappointed by Treasury decision to end emergency loan programs

Charles Evans, President of the Federal Reserve Bank of Chicago, speaks during a conference at the Federal Reserve Bank of Chicago on June 04, 2019 Scott Olson/Getty Images Chicago Federal Reserve President Charles Evans said Friday he was disappointed that the Treasury Department decided not to extend some Fed emergency loan programs to small businesses and municipalities, which have been a buffer during the COVID-19 shutdowns.

Continue reading